Zhitong Financial App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group has obtained the China National Drug Administration (CNDA) drug production registration approval for low-calcium peritoneal dialysis solution (bicarbonate G 1.5%), peritoneal dialysis solution (bicarbonate-G 2.5%), peritoneal dialysate (bicarbonate-G 4.25%), and low-calcium peritoneal dialysis solution (bicarbonate-G 4.25%), all of which are 2000ml and are considered to be Class 3 chemical drugs. Consistency evaluation, including low-calcium peritoneal dialysates (bicarbonate- G 4.25%) is the third domestic company to be approved. These products are mainly used for peritoneal dialysis in patients with chronic renal failure, and are used when hypermagnesemia has not been sufficiently improved.
The Group continues to strategically lay out the field of renal replacement therapy, and its products cover peritoneal dialysis solutions, hemofiltration replacement solutions, etc. The four peritoneal dialysis solutions approved this time are all two-chamber sachets with a bicarbonate buffer system. They are designed to be separated and stored and mixed before temporary use. The process difficulty and technical barriers are high. These products are combined with 1.5%/2.5%/4.25% glucose concentrations and standard calcium and low calcium formulations to meet the clinical needs of patients with different conditions and abnormal calcium and magnesium. These products are an emerging upgraded variety in the field of peritoneal dialysis. The number of domestic approved companies is limited, and the competitive pattern is relatively good. Compared with traditional lactate preparations, there is room for differentiated pricing. As clinical awareness increases, there is broad market penetration space.
After approval, the Group has formed a leading domestic peritoneal dialysate product matrix with a complete layout, covering multiple technical routes and specifications for lactate and bicarbonate, and has achieved stable production and controlled quality by relying on mature large infusion platforms. As an important treatment for end-stage nephropathy, peritoneal dialysis has the convenience of home operation and flexible schedule. It can complement and be used sequentially with hemodialysis to prolong the patient's life cycle, and the clinical needs are rigid and sufficient. Compared with hemodialysis, the penetration rate of the domestic peritoneal dialysis market has a lot of room for improvement, and the growth prospects are broad. This approval will further improve the Group's nephrology dialysis pipeline and strengthen the competitiveness of the renal replacement therapy sector.
The Board of Directors is also pleased to announce that the Group has obtained drug production registration approval for arginine hydrochloride injection (200ml: 20g) from the State Drug Administration. It is the second domestic company to be approved. It is considered a Class 3 chemical. It is considered to have passed the consistency evaluation. It is mainly used to urgently reduce blood ammonia concentrations when oral preparations cannot control the acute worsening of hyperammonemia in certain diseases.
The Group continues to lay out emergency and critical care treatment pipelines. The approved arginine hydrochloride injection (200ml: 20g) is a therapeutic large-capacity infusion. Compared with the currently widely used small-volume ampoule dosage form, this product does not require clinical dilution and is easy to use in critical emergency situations. This approval further enriches the Group's therapeutic infusion product line.